Univariate analysis for clinical, radiological characteristics and pulmonary embolism recurrence outcome in SSPE cases
| Characteristic . | Categories . | Recurrence: no (n = 188), n (%) . | Recurrence: yes (n = 18), n (%) . | Fisher's exact test P (2-tailed) . |
|---|---|---|---|---|
| Sex | Female | 82 (43.6) | 5 (27.8) | .2212 |
| Male | 106 (56.4) | 13 (72.2) | ||
| ECOG performance status | 0 | 43 (23.2) | 3 (16.7) | .8621 |
| 1 | 84 (45.4) | 10 (55.6) | ||
| 2 | 31 (16.8) | 2 (11.1) | ||
| 3 | 22 (11.9) | 3 (16.6) | ||
| 4 | 5 (2.7) | 0 | ||
| Cancer type | Lung | 33 (17.6) | 6 (33.3) | .3750 |
| Colorectal | 17 (9.0) | 1 (5.6) | ||
| Breast | 17 (9.0) | 1 (5.6) | ||
| Hematologic | 14 (7.4) | 3 (16.7) | ||
| Urologic | 13 (6.9) | 4 (22.2) | ||
| Gynecologic | 15 (8.0) | 0 | ||
| Sarcoma | 14 (7.4) | 1 (5.6) | ||
| Esophageal | 11 (5.9) | 0 | ||
| Pancreatic | 8 (4.3) | 1 (5.6) | ||
| Gastric | 6 (3.2) | 0 | ||
| Other | 38 (2.0) | 3 (16.7) | ||
| AJCC stage | 1 | 8 (4.6) | 1 (6.3) | .5152 |
| 2 | 12 (6.9) | 2 (12.5) | ||
| 3 | 27 (15.5) | 1 (6.3) | ||
| 4 | 127 (73.0) | 12 (75.0) | ||
| Cancer status | Active disease | 162 (86.2) | 15 (83.3) | .8613 |
| Remission within 2 y | 15 (8.0) | 2 (11.1) | ||
| >2 y since remission | 11 (5.9) | 1 (5.6) | ||
| Central nervous tumor or metastasis | Yes | 19 (10.1) | 2 (11.1) | 1.000 |
| No | 169 (89.9) | 16 (88.9) | ||
| Lung or pleural metastasis | Yes | 92 (48.9) | 9 (50.0) | 1.000 |
| No | 96 (51.1) | 9 (50.0) | ||
| Liver metastasis | Yes | 39 (20.7) | 4 (22.2) | 1.000 |
| No | 149 (79.3) | 14 (77.8) | ||
| Active chemotherapy | Yes | 100 (53.2) | 8 (44.4) | .4675 |
| No | 85 (45.2) | 10 (55.6) | ||
| Endocrine therapy | Yes | 10 (5.3) | 1 (5.6) | 1.000 |
| No | 175 (93.1) | 17 (94.4) | ||
| Antiangiogenic therapy | Yes | 18 (9.6) | 3 (16.7) | .4079 |
| No | 167 (88.8) | 15 (83.3) | ||
| Major surgery within 30 d before SSPE | Yes | 22 (11.7) | 3 (16.7) | .4641 |
| No | 166 (88.3) | 15 (83.3) | ||
| History of venous thrombosis | Yes | 20 (10.6) | 3 (16.7) | .4318 |
| No | 168 (89.4) | 15 (83.3) | ||
| Other indication for long-term anticoagulation | Yes | 28 (14.9) | 2 (11.1) | 1.000 |
| No | 160 (85.1) | 16 (88.9) | ||
| Concurrent antiplatelet therapy | Yes | 33 (17.6) | 2 (11.1) | .7438 |
| No | 155 (82.4) | 16 (88.9) | ||
| SSPE treatment | Other | 27 (14.4) | 4 (22.2) | .4860 |
| Anticoagulation | 161 (85.6) | 14 (77.8) | ||
| Obesity | Yes | 63 (33.5) | 5 (27.8) | .7946 |
| No | 125 (66.5) | 13 (72.2) | ||
| Concurrent use of erythropoietin agents | Yes | 1 (0.5) | 0 | 1.000 |
| No | 187 (99.5) | 18 (100) | ||
| Type of CT study | CT chest PE protocol | 61 (32.4) | 7 (38.9) | .6051 |
| CT chest with contrast | 127 (67.6) | 11 (61.1) | ||
| SSPE, no/ | 1 | 125 (66.5) | 14 (77.8) | .5432 |
| 2 | 20 (10.6) | 2 (11.1) | ||
| 3 | 33 (17.6) | 1 (5.6) | ||
| 4 | 1 (0.5) | 0 | ||
| SSPE location | Right sided | 117 (62.2) | 15 (83.3) | .2419 |
| Left sided | 32 (17.0) | 1 (5.6) | ||
| Bilateral | 39 (20.7) | 2 (11.1) | ||
| RV/LV ratio > 1 | Yes | 11 (5.9) | 0 | .6038 |
| No | 177 (94.1) | 18 (100) |
| Characteristic . | Categories . | Recurrence: no (n = 188), n (%) . | Recurrence: yes (n = 18), n (%) . | Fisher's exact test P (2-tailed) . |
|---|---|---|---|---|
| Sex | Female | 82 (43.6) | 5 (27.8) | .2212 |
| Male | 106 (56.4) | 13 (72.2) | ||
| ECOG performance status | 0 | 43 (23.2) | 3 (16.7) | .8621 |
| 1 | 84 (45.4) | 10 (55.6) | ||
| 2 | 31 (16.8) | 2 (11.1) | ||
| 3 | 22 (11.9) | 3 (16.6) | ||
| 4 | 5 (2.7) | 0 | ||
| Cancer type | Lung | 33 (17.6) | 6 (33.3) | .3750 |
| Colorectal | 17 (9.0) | 1 (5.6) | ||
| Breast | 17 (9.0) | 1 (5.6) | ||
| Hematologic | 14 (7.4) | 3 (16.7) | ||
| Urologic | 13 (6.9) | 4 (22.2) | ||
| Gynecologic | 15 (8.0) | 0 | ||
| Sarcoma | 14 (7.4) | 1 (5.6) | ||
| Esophageal | 11 (5.9) | 0 | ||
| Pancreatic | 8 (4.3) | 1 (5.6) | ||
| Gastric | 6 (3.2) | 0 | ||
| Other | 38 (2.0) | 3 (16.7) | ||
| AJCC stage | 1 | 8 (4.6) | 1 (6.3) | .5152 |
| 2 | 12 (6.9) | 2 (12.5) | ||
| 3 | 27 (15.5) | 1 (6.3) | ||
| 4 | 127 (73.0) | 12 (75.0) | ||
| Cancer status | Active disease | 162 (86.2) | 15 (83.3) | .8613 |
| Remission within 2 y | 15 (8.0) | 2 (11.1) | ||
| >2 y since remission | 11 (5.9) | 1 (5.6) | ||
| Central nervous tumor or metastasis | Yes | 19 (10.1) | 2 (11.1) | 1.000 |
| No | 169 (89.9) | 16 (88.9) | ||
| Lung or pleural metastasis | Yes | 92 (48.9) | 9 (50.0) | 1.000 |
| No | 96 (51.1) | 9 (50.0) | ||
| Liver metastasis | Yes | 39 (20.7) | 4 (22.2) | 1.000 |
| No | 149 (79.3) | 14 (77.8) | ||
| Active chemotherapy | Yes | 100 (53.2) | 8 (44.4) | .4675 |
| No | 85 (45.2) | 10 (55.6) | ||
| Endocrine therapy | Yes | 10 (5.3) | 1 (5.6) | 1.000 |
| No | 175 (93.1) | 17 (94.4) | ||
| Antiangiogenic therapy | Yes | 18 (9.6) | 3 (16.7) | .4079 |
| No | 167 (88.8) | 15 (83.3) | ||
| Major surgery within 30 d before SSPE | Yes | 22 (11.7) | 3 (16.7) | .4641 |
| No | 166 (88.3) | 15 (83.3) | ||
| History of venous thrombosis | Yes | 20 (10.6) | 3 (16.7) | .4318 |
| No | 168 (89.4) | 15 (83.3) | ||
| Other indication for long-term anticoagulation | Yes | 28 (14.9) | 2 (11.1) | 1.000 |
| No | 160 (85.1) | 16 (88.9) | ||
| Concurrent antiplatelet therapy | Yes | 33 (17.6) | 2 (11.1) | .7438 |
| No | 155 (82.4) | 16 (88.9) | ||
| SSPE treatment | Other | 27 (14.4) | 4 (22.2) | .4860 |
| Anticoagulation | 161 (85.6) | 14 (77.8) | ||
| Obesity | Yes | 63 (33.5) | 5 (27.8) | .7946 |
| No | 125 (66.5) | 13 (72.2) | ||
| Concurrent use of erythropoietin agents | Yes | 1 (0.5) | 0 | 1.000 |
| No | 187 (99.5) | 18 (100) | ||
| Type of CT study | CT chest PE protocol | 61 (32.4) | 7 (38.9) | .6051 |
| CT chest with contrast | 127 (67.6) | 11 (61.1) | ||
| SSPE, no/ | 1 | 125 (66.5) | 14 (77.8) | .5432 |
| 2 | 20 (10.6) | 2 (11.1) | ||
| 3 | 33 (17.6) | 1 (5.6) | ||
| 4 | 1 (0.5) | 0 | ||
| SSPE location | Right sided | 117 (62.2) | 15 (83.3) | .2419 |
| Left sided | 32 (17.0) | 1 (5.6) | ||
| Bilateral | 39 (20.7) | 2 (11.1) | ||
| RV/LV ratio > 1 | Yes | 11 (5.9) | 0 | .6038 |
| No | 177 (94.1) | 18 (100) |